Drug intelligence / Profile preview

CMAB022

Development stage: Preclinical
Lead developer: Mabpharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

CMAB022 is a biosimilar monoclonal antibody candidate being developed by Taizhou Mabtech Pharmaceutical, a subsidiary of MabPharm Limited. It targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), effectively blocking their signaling pathways. This mechanism is identical to that of the reference product, ustekinumab (Stelara). CMAB022 is intended for the treatment of various inflammatory and autoimmune conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is currently in the preclinical stage of development, utilizing self-developed innovative technology platforms.

Other names: ustekinumab biosimilar

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on CMAB022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMAB022.

Explore the full profile